Five recurrent BRCA1/2 mutations are responsible for cancer predisposition in the majority of Slovenian breast cancer families.
BACKGROUND
Both recurrent and population specific mutations have been found in different areas of the world and more specifically in ethnically defined or isolated populations. The population of Slovenia has over several centuries undergone limited mixing with surrounding populations. The current study was aimed at establishing the mutation spectrum of BRCA1/2 in the Slovenian breast/ovarian cancer families taking advantage of a complete cancer registration database. A second objective was to determine the cancer phenotype of these families.


METHODS
The original population database was composed of cancer patients from the Institute of Oncology Ljubljana in Slovenia which also includes current follow-up status on these patients. The inclusion criteria for the BRCA1/2 screening were: (i) probands with at least two first degree relatives with breast and ovarian cancer; (ii) probands with only two first degree relatives of breast cancer where one must be diagnosed less than 50 years of age; and (iii) individual patients with breast and ovarian cancer, bilateral breast cancer, breast cancer diagnosed before the age of 40 and male breast cancer without any other cancer in the family.


RESULTS
Probands from 150 different families met the inclusion criteria for mutation analysis of which 145 consented to testing. A BRCA1/2 mutation was found in 56 (39%). Two novel large deletions covering consecutive exons of BRCA1 were found. Five highly recurrent specific mutations were identified (1806C>T, 300T>G, 300T>A, 5382insC in the BRCA1 gene and IVS16-2A>G in the BRCA2 gene). The IVS16-2A>G in the BRCA2 gene appears to be a unique founder mutation in the Slovenian population. A practical implication is that only 4 PCR fragments can be used in a first screen and reveal the cancer predisposing mutation in 67% of the BRCA1/2 positive families. We also observed an exceptionally high frequency of 4 different pathogenic missense mutations, all affecting one of the cryptic cysteine residues of the BRCA1 Ring Finger domain.


CONCLUSIONS
A high mutation detection rate and the frequent occurrence of a limited array of recurring mutations facilitate BRCA1/2 mutation screening in Slovenian families.
Krajc
Mateja
M
Institute of Oncology Ljubljana, Zaloska 2, 1000 Ljubljana, Slovenia. mkrajc@onko-i.si
Teugels
Erik
E
Zgajnar
Janez
J
Goelen
Guido
G
Besic
Nikola
N
Novakovic
Srdjan
S
Hocevar
Marko
M
De Grève
Jacques
J
D000328:Adult; D001943:Breast Neoplasms / Q000235:genetics*; D018567:Breast Neoplasms, Male / Q000235:genetics; D004252:DNA Mutational Analysis; D005260:Female; D019398:Genes, BRCA1; D024522:Genes, BRCA2; D020022:Genetic Predisposition to Disease; D005820:Genetic Testing; D005838:Genotype; D006801:Humans; D008297:Male; D009154:Mutation; D020125:Mutation, Missense; D009386:Neoplastic Syndromes, Hereditary / Q000235:genetics*; D010051:Ovarian Neoplasms / Q000235:genetics; D010641:Phenotype; D017384:Sequence Deletion; D017524:Slovenia
J Med Genet. 2004 Mar;41(3):e23
14985394
Nat Genet. 1997 Jan;15(1):103-5
8988179
J Med Genet. 1997 Nov;34(11):884-8
9391879
J Med Genet. 1999 Apr;36(4):304-8
10227398
Lab Invest. 2003 Mar;83(3):387-96
12649339
Clin Genet. 2003 Dec;64(6):502-8
14986830
Nat Genet. 1996 May;13(1):117-9
8673089
Fam Cancer. 2004;3(1):1-10
15131399
Nature. 1995 Dec 21-28;378(6559):789-92
8524414
Nat Genet. 1995 Jun;10(2):208-12
7663517
Cancer Epidemiol Biomarkers Prev. 2000 Nov;9(11):1251-4
11097234
Fam Cancer. 2005;4(2):77-84
15951956
Int J Cancer. 2000 Jun 1;86(5):737-40
10797299
Curr Opin Struct Biol. 1996 Jun;6(3):395-401
8804826
N Engl J Med. 1997 May 15;336(20):1409-15
9145677
Breast Cancer Res. 2000;2(4):307-10
11056688
Nat Genet. 1997 Nov;17(3):341-5
9354803
Oncol Rep. 1999 Nov-Dec;6(6):1435-8
10523726
Hum Mutat. 1998;12(3):215
10660329
Eur J Cancer. 2000 Oct;36(16):2083-9
11044645
Int J Cancer. 1999 Sep 24;83(1):5-9
10449599
JAMA. 1997 Mar 26;277(12):997-1003
9091675
Br J Cancer. 2000 Apr;82(7):1266-70
10755399
Br J Cancer. 2000 Sep;83(6):737-42
10952777
Hum Mutat. 2001 Aug;18(2):163-4
11462242
N Engl J Med. 1997 May 15;336(20):1401-8
9145676
BMC Cancer. 2006 Jun 09;6:156
16764716
Int J Cancer. 1998 Nov 23;78(5):581-6
9808526
Nat Genet. 1995 Dec;11(4):428-33
7493024
Science. 1994 Oct 7;266(5182):66-71
7545954
Cancer. 1981 Jun 1;47(11):2730-9
7260865
Hum Mutat. 2006 Jul;27(7):654-66
16683254
Am J Hum Genet. 1998 Mar;62(3):676-89
9497246
Eur J Hum Genet. 2002 Dec;10(12):879-82
12461697
Breast Cancer Res. 2005;7(5):R728-36
16168118